Discontinued — last reported Q1 '18
Eli Lilly Allowance for Doubtful Accounts Receivable (Current) increased by 34.8% to $21.70M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 38.2%, from $15.70M to $21.70M. Over 4 years (FY 2020 to FY 2024), Allowance for Doubtful Accounts Receivable (Current) shows a downward trend with a -12.9% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase may signal deteriorating customer credit quality or a weakening economic environment.
This is a contra-asset account representing the portion of current accounts receivable that the company estimates will n...
Commonly reported by all companies with significant B2B sales; peers may label this as bad debt reserve.
allowance_for_doubtful_accounts_receivable_current| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $23.90M | $24.10M | $22.50M | $22.00M | $19.20M | $17.70M | $16.00M | $14.00M | $13.80M | $13.40M | $14.80M | $14.30M | $14.40M | $15.70M | $14.90M | $15.50M | $16.10M | $21.70M |
| QoQ Change | — | +0.8% | -6.6% | -2.2% | -12.7% | -7.8% | -9.6% | -12.5% | -1.4% | -2.9% | +10.4% | -3.4% | +0.7% | +9.0% | -5.1% | +4.0% | +3.9% | +34.8% |
| YoY Change | — | — | — | — | -19.7% | -26.6% | -28.9% | -36.4% | -28.1% | -24.3% | -7.5% | +2.1% | +4.3% | +17.2% | +0.7% | +8.4% | +11.8% | +38.2% |
We use cookies for analytics. See our Privacy and Cookie Policy.